{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:42:47Z","timestamp":1778629367178,"version":"3.51.4"},"reference-count":23,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1843118N"],"award-info":[{"award-number":["1843118N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019353","name":"Belgian Health Care Knowledge Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100019353","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2021,7,24]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4\u2005units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT<jats:sub>50<\/jats:sub>)) \u22651\/320 was the product of choice for the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median (interquartile range) volume of 884 (806\u2013906)\u2005mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT<jats:sub>50<\/jats:sub>) \u22651\/320. Median time from onset of symptoms to randomisation was 7\u2005days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267)<jats:italic>versus<\/jats:italic>control 84.05% (n=137)) (OR 0.99, 95% CI 0.59\u20131.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Transfusion of 4\u2005units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.01724-2021","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T16:16:09Z","timestamp":1629994569000},"page":"2101724","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma"],"prefix":"10.1183","volume":"59","author":[{"given":"Timothy","family":"Devos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-280X","authenticated-orcid":false,"given":"Quentin","family":"Van Thillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Compernolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e9","family":"Najdovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-6849","authenticated-orcid":false,"given":"Nicolas","family":"Dauby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Jadot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Leys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Loof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Seyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martial","family":"Moonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Moutschen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Van Regenmortel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin K.","family":"Ari\u00ebn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Barbezange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Betrains","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutien","family":"Garigliany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias M.","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4068-7228","authenticated-orcid":false,"given":"Iwein","family":"Gyselinck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Schauwvlieghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5616-8548","authenticated-orcid":false,"given":"Laurens","family":"Liesenborghs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Belmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8698-2858","authenticated-orcid":false,"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Meyfroidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"2024102102371784000_59.2.2101724.1","unstructured":"World Health Organization . WHO coronavirus (COVID-19) dashboard with vaccination data. 2021. https:\/\/covid19.who.int Date last accessed: 16 July 2021."},{"key":"2024102102371784000_59.2.2101724.2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2020.4031","article-title":"Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"2024102102371784000_59.2.2101724.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30243-7"},{"key":"2024102102371784000_59.2.2101724.4","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.lanepe.2020.100019","article-title":"The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium","volume":"2","author":"Taccone","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"2024102102371784000_59.2.2101724.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2024102102371784000_59.2.2101724.6","first-page":"1491","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"84","year":"2021","journal-title":"N Engl J Med"},{"key":"2024102102371784000_59.2.2101724.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030340"},{"key":"2024102102371784000_59.2.2101724.8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2101643"},{"key":"2024102102371784000_59.2.2101724.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"2024102102371784000_59.2.2101724.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184"},{"key":"2024102102371784000_59.2.2101724.11","doi-asserted-by":"crossref","first-page":"917.e1","DOI":"10.1016\/j.cmi.2021.02.029","article-title":"A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel","volume":"27","author":"Goldberg","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2024102102371784000_59.2.2101724.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939"},{"key":"2024102102371784000_59.2.2101724.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031304"},{"key":"2024102102371784000_59.2.2101724.14","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/s41467-021-23469-2","article-title":"Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection","volume":"12","author":"Gharbharan","year":"2020","journal-title":"Nat Commun"},{"key":"2024102102371784000_59.2.2101724.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033700"},{"key":"2024102102371784000_59.2.2101724.16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jama.2021.2747","article-title":"Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"325","author":"Janiaud","year":"2021","journal-title":"JAMA"},{"key":"2024102102371784000_59.2.2101724.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031893"},{"key":"2024102102371784000_59.2.2101724.18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1186\/s13063-020-04876-0","article-title":"A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial","volume":"21","author":"Devos","year":"2020","journal-title":"Trials"},{"key":"2024102102371784000_59.2.2101724.19","doi-asserted-by":"publisher","DOI":"10.2307\/2291635"},{"key":"2024102102371784000_59.2.2101724.20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00897-7"},{"key":"2024102102371784000_59.2.2101724.21","doi-asserted-by":"crossref","first-page":"e150646","DOI":"10.1172\/JCI150646","article-title":"A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19","volume":"131","author":"O'Donnell","year":"2021","journal-title":"J Clin Invest"},{"key":"2024102102371784000_59.2.2101724.22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/bjh.17266","article-title":"Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies","volume":"192","author":"Betrains","year":"2021","journal-title":"Br J Haematol"},{"key":"2024102102371784000_59.2.2101724.23","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01724-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:47:02Z","timestamp":1740376022000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01724-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,10]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1183\/13993003.01724-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01724-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]}}}